Antiplatelet therapy to prevent hemodialysis vascular access failure: systematic review and meta-analysis.

BACKGROUND Hemodialysis vascular access failure occurs often and increases morbidity for people on hemodialysis therapy. Antiplatelet agents may prevent hemodialysis vascular access failure, but potentially may be hazardous in people with end-stage kidney disease who have impaired hemostasis. STUDY DESIGN Systematic review and meta-analysis of randomized controlled trials. SETTING & POPULATION Adults on long-term hemodialysis therapy. SELECTION CRITERIA Trials evaluating hemodialysis vascular access outcomes identified by searches in Cochrane CENTRAL and Renal Group Trial Registers and Embase, without language restriction. INTERVENTION Antiplatelet therapy. OUTCOMES Hemodialysis vascular access failure (thrombosis or loss of patency), failure to attain vascular access suitable for dialysis, need for intervention to attain patency or assist maturation, major bleeding, minor bleeding, and antiplatelet treatment withdrawal. Treatment effects were summarized as RRs with 95% CIs using random-effects meta-analysis. RESULTS 21 eligible trials (4,826 participants) comparing antiplatelet treatment with placebo or no treatment were included. 12 trials (3,118 participants) started antiplatelet therapy around the time of dialysis vascular access surgery and continued treatment for approximately 6 months. Antiplatelet treatment reduced fistula failure (thrombosis or loss of patency) by one-half (6 trials, 1,222 participants; RR, 0.49; 95% CI, 0.30-0.81) but had uncertain effects on graft patency and attaining fistula or graft function suitable for dialysis. Overall, antiplatelet treatment had uncertain effects on major bleeding. LIMITATIONS Unclear or high risk of bias in most trials and few trial data, particularly for antiplatelet effects on graft function and vascular access suitability for dialysis. CONCLUSIONS Antiplatelet treatment protects fistula from thrombosis or loss of patency, but has little or no effect on graft patency and uncertain effects on vascular access maturation for dialysis and major bleeding. Interventions that demonstrably improve vascular access suitability for dialysis are needed.

[1]  A. Da Silva,et al.  Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts. , 2015, The Cochrane database of systematic reviews.

[2]  M. Tonelli,et al.  Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial. , 2012, JAMA.

[3]  G. Beck,et al.  Use of aspirin associates with longer primary patency of hemodialysis grafts. , 2011, Journal of the American Society of Nephrology : JASN.

[4]  C. White,et al.  Antiplatelet agents for the prevention of arteriovenous fistula and graft thrombosis: a meta analysis , 2010, International journal of clinical practice.

[5]  G. Beck,et al.  Effect of dipyridamole plus aspirin on hemodialysis graft patency. , 2009, The New England journal of medicine.

[6]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement , 2009, BMJ : British Medical Journal.

[7]  A. Ehsanpour,et al.  Randomized controlled trial of clopidogrel to prevent primary arteriovenous fistula failure in hemodialysis patients , 2009, Indian journal of nephrology.

[8]  Stephane Heritier,et al.  Preventing AVF thrombosis: the rationale and design of the Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study , 2009, BMC nephrology.

[9]  G. Beck,et al.  Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. , 2008, JAMA.

[10]  I. Abdul-Rahman,et al.  Warfarin Versus Aspirin in Preventing Tunneled Hemodialysis Catheter Thrombosis: A Prospective Randomized Study , 2007 .

[11]  Simona Gioberge,et al.  ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[12]  E. Ritz,et al.  Prevention of p.o. clotting of av. cimino fistulae with Acetylsalicyl acid results of a prospective double blind study , 1974, Klinische Wochenschrift.

[13]  T. Stijnen,et al.  Radiocephalic wrist arteriovenous fistula for hemodialysis: meta-analysis indicates a high primary failure rate. , 2004, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[14]  J. Hux,et al.  Late creation of vascular access for hemodialysis and increased risk of sepsis. , 2004, Journal of the American Society of Nephrology : JASN.

[15]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[16]  P. Peduzzi,et al.  Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. , 2003, Journal of the American Society of Nephrology : JASN.

[17]  M. Robbin,et al.  Increasing arteriovenous fistulas in hemodialysis patients: problems and solutions. , 2002, Kidney international.

[18]  A. Mattioli,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[19]  Catherine Sudlow,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[20]  H. Mulec,et al.  Effects of ticlopidine in AV-fistula surgery in uremia. Fistula Study Group. , 1998, Scandinavian journal of urology and nephrology.

[21]  J. Himmelfarb,et al.  Anti-platelet therapy in graft thrombosis: results of a prospective, randomized, double-blind study. , 1994, Kidney international.

[22]  J. Marx,et al.  Low-dose aspirin does not prevent thrombovascular accidents in low-risk haemodialysis patients during treatment with recombinant human erythropoietin. , 1994, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[23]  C. Fiskerstrand,et al.  Double-blind randomized trial of the effect of ticlopidine in arteriovenous fistulas for hemodialysis. , 1985, Artificial organs.

[24]  H. Mulec,et al.  Thromboprophylactic effect of ticlopidine in arteriovenous fistulas for haemodialysis. , 1985, Scandinavian journal of urology and nephrology.

[25]  S. Koshikawa,et al.  Antithrombotic therapy with ticlopidine in chronic renal failure patients on maintenance hemodialysis--a multicenter collaborative double blind study. , 1980, Thrombosis research.

[26]  P. Majerus,et al.  Prevention of thrombosis in patients on hemodialysis by low-dose aspirin. , 1979, The New England journal of medicine.

[27]  J. Hirsh,et al.  Arteriovenous-shunt thrombosis. Prevention by sulfinpyrazone. , 1974, The New England journal of medicine.